Jing Xuefeng, Sonoki Takashi, Miyajima Masayasu, Sawada Takahiro, Terada Nanako, Takemura Shigeki, Sakaguchi Kazushige
Departments of Molecular Cell Biology and Molecular Medicine, Institute of Advanced Medicine, Wakayama Medical University, School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Departments of Hematology/Oncology, University Hospital, Wakayama Medical University, School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
Cancer Med. 2016 Jun;5(6):1214-27. doi: 10.1002/cam4.670. Epub 2016 Feb 29.
EphA4 belongs to the largest family of receptor tyrosine kinases (RTKs). Although EphA4 is highly expressed in the central nervous system, EphA4 has also been implicated in cancer progression. Most of the studies focus on the expression and function in tumor cells. It is unknown whether EphA4-deleted microenvironment affects tumor progression. Some of cancers in animals and humans, such as 4T1 cancer cells, are known to produce a large amount of granulocyte colony-stimulating factors (G-CSF/Csf3) which can stimulate myeloproliferation, such as myeloid-derived suppressor cells (MDSCs) leading to a poor recipient prognosis. We isografted 4T1 breast cancer cells into both EphA4-knockout and control wild-type female littermate mice. The results showed that the EphA4-deleted host could inhibit primary tumor growth and tumor metastasis mainly by decreasing the amount of IGF1 synthesis in the circulation and locally tissues. The EphA4-deleted microenvironment and delayed tumor development reduced the production of G-CSF resulting in the decrease of splenomegaly and leukemoid reaction including MDSCs, which in turn inhibit the tumor progression. This inhibition can be reversed by supplying the mice with IGF1. However, an excess of IGF1 supply over demand to the control mice could not further accelerate the tumor growth and metastasis. A better understanding and re-evaluation of the main role of IGF1 in regulating tumor progression could further enhance our cognition of the tumor development niche. Our findings demonstrated that EphA4-deleted microenvironment impairs tumor-supporting conditions.
Host EphA4 expression regulates cancer development mainly via EphA4-mediated IGF1 synthesis signal. Thus, targeting this signaling pathway may provide a potential therapeutic option for cancer treatment.
EphA4属于受体酪氨酸激酶(RTK)的最大家族。尽管EphA4在中枢神经系统中高度表达,但它也与癌症进展有关。大多数研究集中在肿瘤细胞中的表达和功能。尚不清楚缺失EphA4的微环境是否会影响肿瘤进展。动物和人类的一些癌症,如4T1癌细胞,已知会产生大量粒细胞集落刺激因子(G-CSF/Csf3),可刺激骨髓增殖,如髓源性抑制细胞(MDSC),导致受体预后不良。我们将4T1乳腺癌细胞移植到EphA4基因敲除和对照野生型雌性同窝小鼠体内。结果表明,缺失EphA4的宿主主要通过减少循环和局部组织中IGF1的合成量来抑制原发性肿瘤生长和肿瘤转移。缺失EphA4的微环境和肿瘤发展延迟减少了G-CSF的产生,导致脾肿大和类白血病反应(包括MDSC)减少,进而抑制肿瘤进展。通过给小鼠提供IGF1可以逆转这种抑制作用。然而,向对照小鼠提供过量的IGF1并不能进一步加速肿瘤生长和转移。更好地理解和重新评估IGF1在调节肿瘤进展中的主要作用可能会进一步增强我们对肿瘤发展生态位的认识。我们的研究结果表明,缺失EphA4的微环境会损害肿瘤支持条件。
宿主EphA4表达主要通过EphA4介导的IGF1合成信号调节癌症发展。因此,靶向该信号通路可能为癌症治疗提供一种潜在的治疗选择。